Change in serum level of abnormal prothrombin after microwave ablation for hepatocellular carcinoma and its clinical significance

Sun Yu; Zhang HongHai; Yuan ChunWang; Li Cong; Hu CaiXia; Cui ShiChang; Zhang YongHong; Zheng JiaSheng

doi:10.3969/j.issn.1001-5256.2019.03.018

Volume 35 Issue 3

Mar. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(3): 542-546

PDF( 1996 KB)

Change in serum level of abnormal prothrombin after microwave ablation for hepatocellular carcinoma and its clinical significance

DOI: 10.3969/j.issn.1001-5256.2019.03.018

Minimally Invasive Interventional Center of Oncology, Beijing YouAn Hospital, Capital Medical University

Research funding:

Received Date: 2018-10-08
Published Date: 2019-03-20

Abstract

Abstract

Objective To investigate the changes in serum levels of des-γ-carboxy-prothrombin ( DCP) and alpha-fetoprotein ( AFP) after microwave ablation in patients with hepatocellular carcinoma ( HCC) , to monitor the recurrence of HCC, and to investigate the associa-tion of serum DCP and AFP levels with the recurrence of HCC. Methods A total of 76 patients who were hospitalized and treated in BeijingYouAn Hospital, Capital Medical University, from December 2015 to February 2018 and were diagnosed with HCC by liver biopsy were en-rolled. The serum levels of DCP and AFP were measured before and after microwave ablation and at the time of recurrence. The Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups, and the Kruskal-Wallis H testwas used for comparison between three groups; the Spearman correlation analysis was used to investigate correlation. Results At 1 week af-ter microwave ablation, the HCC patients had significant reductions in the serum levels of DCP and AFP ( Z = 6. 854 and 6. 246, both P <0. 01) , which further decreased at 1 month after microwave ablation ( DCP: Z = 11. 639 and 4. 786, both P < 0. 01; AFP: Z = 10. 058 and3. 812, both P < 0. 01) . Of all 76 HCC patients, 59 experienced recurrence, and the serum levels of DCP and AFP at the time of recurrencewere significantly higher than the levels at 1 week and 1 month after microwave ablation ( DCP: Z =-4. 671 and-8. 521, both P < 0. 01;AFP: Z =-3. 423 and-6. 311, both P < 0. 01) . Before microwave ablation, the recurrence group had significantly higher serum levels ofDCP and AFP than the non-recurrence group ( Z =-3. 010 and-2. 387, P = 0. 003 or P = 0. 017) ; at 1 month after microwave ablation, the recurrence group had a significantly higher serum level of DCP than the non-recurrence group ( Z =-3. 498, P < 0. 001) . In the re-currence group, the patients with extrahepatic distant metastasis or vascular invasion had a significantly higher serum level of DCP than thosewith intrahepatic recurrence alone before and at 1 month after microwave ablation ( χ2= 23. 597 and 18. 228, both P < 0. 01) . Correlation a-nalysis showed that in HCC patients with recurrence, serum DCP level before and at 1 month after microwave ablation was negatively correlated with time to recurrence ( r =-0. 500 and-0. 651, both P < 0. 01) . Conclusion Monitoring of serum DCP level before and after microwave ablation in HCC patients helps to judge the clinical effect of microwave ablation and predict recurrence and prognosis.
- carcinoma, hepatocellular,
- catheter ablation,
- alpha-fetoproteins,
- des-γ-carboxy-prothrombin

FullText(HTML)

References(22)

References

[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global Canc-er Statistics 2018:Globocan estimates of incidence and mor-tality worldwide for 36 cancers in 185 countries[J]. CA CancerJ Clin, 2018, 68 (6) :394-424.

[2] ZHANG M, GAO Z, TAN GF, et al. Effect of transcatheter ar-terial chemoembolization combined with ultrasound-guidedmicrowave ablation in the treatment of primary hepatocellular-carcinoma[J]. China Med Herald, 2017, 14 (29) :103-106. (in Chinese) 张猛, 高众, 谭贵芳, 等.肝动脉化疗栓塞联合超声引导下微波消融治疗原发性肝癌的效果分析[J].中国医药导报, 2017, 14 (29) :103-106.

[3] LI D, KANG J, MADOFF DC. Locally ablative therapies for pri-mary and metastatic liver cancer[J]. Expert Rev Anticancer T-her, 2014, 14 (8) :931-945.

[4] HU CX, ZHENG JS, LIN W, et al. Analysis of risk factors forearly recurrence after microwave ablation for primary hepato-cellular carcinoma[J]. J Clin Hepatol, 2015, 31 (2) :228-231. (in Chinese) 扈彩霞, 郑加生, 林伟, 等.原发性肝癌微波消融术后早期复发危险因素分析[J].临床肝胆病杂志, 2015, 31 (2) :228-231.

[5] FUJIKAWA T, SHIRAHA H, YAMAMOTO K. Significance ofdes-gamma-carboxy prothrombin production in hepatocel-lular carcinoma[J]. Acta Med Okayama, 2009, 63 (6) :299-304.

[6] National Health and Family Planning Commission of the People'sRepublic of China. Diagnosis, management, and treatment ofhepatocellular carcinoma (V2017) [J]. J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) 中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431.

[7] LU NN, ZHANG YH, WANG HY, et al. Value of serum alpha-fetoprotein and protein induced by vitamin K absence or an-tagonist-II in pathological diagnosis of hepatocellular carcino-ma[J]. J Clin Hepatol, 2017, 33 (11) :2162-2165. (in Chi-nese) 鹿宁宁, 张英华, 王海燕, 等.血清甲胎蛋白联合维生素K缺乏或拮抗剂Ⅱ诱导蛋白在肝细胞癌病理诊断中的应用价值[J].临床肝胆病杂志, 2017, 33 (11) :2162-2165.

[8] PARK H, PARK JY. Clinical significance of AFP and PIVKA-IIresponses for monitoring treatment outcomes and predictingprognosis in patients with hepatocellular carcinoma[J]. Bi-omed Res Int, 2013:310427.

[9] KIM DY, PAIK YH, AHN SH, et al. PIVKA-II is a useful tumormarker for recurrent hepatocellular carcinoma after surgical re-section[J]. Oncology, 2007, 72 (Suppl 1) :52-57.

[10] N'KONTCHOU G, MAHAMOUDI A, AOUT M, et al. Radiofre-quency ablation of hepatocellular carcinoma:Long-term re-sults and prognostic factors in 235 western patients with cirrho-sis[J]. Hepatology, 2009, 50 (5) :1475-1483.

[11] TOYODA H, KUMADA T, KANEOKA Y, et al. Prognostic val-ue of pretreatment levels of tumor markers for hepatocellularcarcinoma on survival after curative treatment of patients withHCC[J]. J Hepatol, 2008, 49 (2) :223-232.

[12] KOBAYASHI M, IKEDA K, KAWAMURA Y, et al. High serumdes-gamma-carboxy prothrombin level predicts poor prog-nosis after radiofrequency ablation of hepatocellular carcinoma[J]. Cancer, 2009, 115 (3) :571-580.

[13] TAKAHASHI S, KUDO M, CHUNG H, et al. PIVKA-II is thebest prognostic predictor in patients with hepatocellular carci-noma after radiofrequency ablation therapy[J]. Oncology, 2008, 75 (Suppl 1) :91-98.

[14] LEE S, RHIM H, KIM YS, et al. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma[J]. Liver Int, 2016, 36 (4) :580-587.

[15] HONG YM, CHO M, YOON KT, et al. Risk factors of early re-currence after curative hepatectomy in hepatocellular carcino-ma[J]. Tumour Biol, 2017, 39 (10) :1010428317720863.

[16] CHON YE, CHOI GH, LEE MH, et al. Combined measure-ment of preoperativeα-fetoprotein and des-γ-carboxyprothrombin predicts recurrence after curative resection in pa-tients with hepatitis-B-related hepatocellular carcinoma[J].Int J Cancer, 2012, 131 (10) :2332-2341.

[17] NANASHIMA A, SUMIDA Y, TOBINAGA S, et al. Postopera-tive changes in protein-induced vitamin K absence or antago-nist II levels after hepatectomy in patients with hepatocellularcarcinoma:Relationship to prognosis[J]. HPB (Oxford) , 2006, 8 (2) :137-141.

[18] KANDA M, TATEISHI R, YOSHIDA H, et al. Extrahepatic me-tastasis of hepatocellular carcinoma:Incidence and risk fac-tors[J]. Liver Int, 2008, 28 (9) :1256-1263.

[19] BAE HM, LEE JH, YOON JH, et al. Protein induced by vita-min K absence or antagonist-II production is a strong predic-tive marker for extrahepatic metastases in early hepatocellularcarcinoma:A prospective evaluation[J]. BMC Cancer, 2011, 11:435.

[20] MIYAAKI H, NAKASHIMA O, KUROGI M, et al. Lens culinarisagglutinin-reactive alpha-fetoprotein and protein induced byvitamin K absence II are potential indicators of a poor progno-sis:A histopathological study of surgically resected hepatocel-lular carcinoma[J]. J Gastroenterol, 2007, 42 (12) :962-968.

[21] GAO FJ, CUI SX, CHEN MH, et al. Des-gamma-carboxyprothrombin increases the expression of angiogenic factors inhuman hepatocellular carcinoma cells[J]. Life Sci, 2008, 83 (23-24) :815-820.

[22] GOTOH M, NAKATANI T, MASUDA T, et al. Prediction of in-vasive activities in hepatocellular carcinomas with special refer-ence to alpha-fetoprotein and des-gamma-carboxypro-thrombin[J]. Jpn J Clin Oncol, 2003, 33 (10) :522-526.

Relative Articles

[1]	Guodong SHI, Zipeng LU, Kuirong JIANG. Diagnosis and treatment of dyspepsia associated with pancreatic tumors[J]. Journal of Clinical Hepatology, 2023, 39(12): 2770-2774. doi: 10.3969/j.issn.1001-5256.2023.12.004
[2]	Yi YAN, Junmei JIA, Yarong GUO. Role of cancer-associated fibroblasts in drug resistance of pancreatic cancer[J]. Journal of Clinical Hepatology, 2022, 38(5): 1203-1208. doi: 10.3969/j.issn.1001-5256.2022.05.048
[3]	Yiyi ZHANG, Min XU. Research advances in the mechanism of tumor microenvironment in pancreatic cancer and related targeted therapy[J]. Journal of Clinical Hepatology, 2022, 38(4): 965-968. doi: 10.3969/j.issn.1001-5256.2022.04.046
[4]	Lina BAI, Ying LIU, Chunxiao TANG, Hongxin PIAO, Zhenhua LIN, Wanshan YANG, Aihua JIN. Mechanism of carrimycin in regulating the biological function of pancreatic cancer cells[J]. Journal of Clinical Hepatology, 2022, 38(12): 2793-2801. doi: 10.3969/j.issn.1001-5256.2022.12.020
[5]	Jing WANG, Bin TAN, Zhijie ZHAO, Haochen ZHONG, Linlin QU. Genomic profile of pancreatic tumor in the coastal regions of Eastern China: A multicenter analysis of 40 cases[J]. Journal of Clinical Hepatology, 2022, 38(2): 409-414. doi: 10.3969/j.issn.1001-5256.2022.02.028
[6]	Feiyu ZHANG, Yakepu ADILA, Jinming ZHAO, Yanhang GAO. New advances in the treatment of pancreatic cancer by targeting tumor microenvironment[J]. Journal of Clinical Hepatology, 2021, 37(9): 2246-2248. doi: 10.3969/j.issn.1001-5256.2021.09.049
[7]	Zhang Yu, Jiang JianXin. Biological role of hypoxic microenvironment in pancreatic cancer[J]. Journal of Clinical Hepatology, 2020, 36(3): 708-712. doi: 10.3969/j.issn.1001-5256.2020.03.054
[8]	Wang Kun, ABUDUREYIMU·Tuerhong, Yang Fan, Liu YaHui, Fu Yu, Zhang Wei. Endoscopic pancreatic stent placement combined with tumor enucleation for benign pancreatic neck tumor: A case report[J]. Journal of Clinical Hepatology, 2019, 35(1): 185-186. doi: 10.3969/j.issn.1001-5256.2019.01.040
[9]	Yang GuiMin, Zhao YunSheng, Wang ChunHua, Jin Liang. Research advances in tumor markers for the diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(1): 199-203. doi: 10.3969/j.issn.1001-5256.2018.01.044
[10]	Zheng SuLi, Zhang TaiPing. An excerpt of laparoscopic surgery for pancreatic neoplasms: the European Association for Endoscopic Surgery clinical consensus conference（2017）[J]. Journal of Clinical Hepatology, 2017, 33(5): 816-819. doi: 10.3969/j.issn.1001-5256.2017.05.004
[11]	Lu: Yan, Zhang XiaoWen. Classification and diagnosis of pancreatic cystic neoplasm[J]. Journal of Clinical Hepatology, 2016, 32(5): 968-971. doi: 10.3969/j.issn.1001-5256.2016.05.039
[12]	Liu Xu, Guo XiaoZhong. Early diagnosis of pancreatic cancer[J]. Journal of Clinical Hepatology, 2016, 32(5): 864-866. doi: 10.3969/j.issn.1001-5256.2016.05.008
[13]	Yang XiaoXiao, Ma Hong. Research advances in tumor markers of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(4): 811-815. doi: 10.3969/j.issn.1001-5256.2016.04.047
[14]	Li Zhao, Zhu JiYe. Treatment of pancreatic neuroendocrine tumor with liver metastases[J]. Journal of Clinical Hepatology, 2015, 31(5): 668-670. doi: 10.3969/j.issn.1001-5256.2015.05.007
[15]	Hou XiaoJia, Jin ZhenDong. Progress in additional new techniques of endoscopic ultrasound in treatment of pancreatic tumors[J]. Journal of Clinical Hepatology, 2015, 31(5): 671-673. doi: 10.3969/j.issn.1001-5256.2015.05.008
[16]	Group of Pancreas Surgery, Chinese Society of Surgery, Chinese Medical Association. Guidelines for the management of pancreatic neuroendocrine neoplasms (2014)[J]. Journal of Clinical Hepatology, 2014, 30(12): 1246-1248. doi: 10.3969/j.issn.1001-5256.2014.12.004
[17]	Li XiaoQing, Qian JiaMing. Differentiation between gastrointestinal neuroendocrine tumors and pancreatic neuroendocrine tumors[J]. Journal of Clinical Hepatology, 2013, 29(7): 492-495. doi: 1001-5256 (2013) 07-0492-04
[18]	Chen Jie. Pathological and differential diagnoses of exocrine pancreatic tumors[J]. Journal of Clinical Hepatology, 2013, 29(1): 45-49.
[19]	Zhang WenYing, Jin ZhenDong. Endoscopic ultrasound -guided treatment for pancreatic tumor[J]. Journal of Clinical Hepatology, 2012, 28(8): 573-575+578.
[20]	Wang YaJun, Sun JiaBang. Experience in diagnosis and treatment of pancreatic cystic tumors[J]. Journal of Clinical Hepatology, 2010, 26(5): 472-475+489.

Supplements(0)

Cited By

Cited by

Periodical cited type(12)

1.	陶丽莹，王宏光，郭庆梅，朴连玉，郭享，阮丽斌，刘时助，孙震. 内镜逆行胰胆管造影联合eyeMax胆胰成像系统直视下液电碎石治疗困难胆管结石效果观察. 临床肝胆病杂志. 2024(02): 351-355 . 本站查看
2.	刘姣，朱巧，范建梅. 内镜逆行胰胆管造影术中使用胰胆直视成像系统联合激光碎石治疗胆总管复杂结石的分析. 医学研究与战创伤救治. 2024(02): 177-180 .
3.	刘晓艳，杨亚苹，韩文雄. 多层螺旋计算机断层扫描技术与磁共振胰胆管造影技术诊断胆总管结石的临床价值. 包头医学. 2024(02): 10-12 .
4.	马丽娜·阿新拜，张立平，王林恒，王允亮，陈润花，孟捷，胡立明，姚玉璞. 经ERCP联合SpyGlass DS治疗的74例不明原因胆管狭窄患者的临床特征分析. 胃肠病学和肝病学杂志. 2024(08): 1037-1044 .
5.	艾合买江·库尔班江，布娅·米然别克，王秋玲，李得阳，高峰. SpyGlass DS系统联合激光碎石法与常规分次治疗胆总管大结石的效果和安全性的对比分析. 中国内镜杂志. 2024(08): 12-17 .
6.	郭志新，王俊，余晓，关天佑，于芳芳. NTrap网篮联合输尿管软镜钬激光术治疗上段输尿管结石的效果及预后观察. 医药论坛杂志. 2024(16): 1703-1707 .
7.	叶国华，姜继豪，王小方. 腹腔镜下联合胆道镜、术中超声及液电碎石仪治疗复杂肝内胆管结石的效果. 中国当代医药. 2024(31): 20-23 .
8.	刘杨军，李纪男. ERCP治疗高龄胆总管结石的效果. 中国老年学杂志. 2024(24): 5935-5937 .
9.	王毅兰，李喆楠，王军民. SpyGlass在胆胰疾病诊治中的研究进展. 河北医科大学学报. 2023(02): 241-245 .
10.	刘炯，汪向飞，江斌. SpyGlass系统在困难胆囊腹腔镜胆囊切除术中的应用价值. 临床外科杂志. 2023(10): 925-927 .
11.	濮天，陈江明，郭旗，蒋东，李子寒，刘付宝，耿小平. 精准肝切除术治疗复发性单侧肝内胆管结石的临床疗效及预后影响因素分析. 中华消化外科杂志. 2022(02): 273-280 .
12.	陈安，柏强善，谭凯. 对胆囊结石合并胆总管结石的老年患者实施腹腔镜胆囊切除术联合内镜逆行胰胆管造影术的临床疗效. 中国内镜杂志. 2022(11): 57-64 .

Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1597) PDF downloads(297)

Change in serum level of abnormal prothrombin after microwave ablation for hepatocellular carcinoma and its clinical significance

DOI: 10.3969/j.issn.1001-5256.2019.03.018